UPC Case Law
Meril GmbH and others v Edwards Lifesciences Corporation
Order of the UPC Court of Appeal of 18 April 2025, UPC CoA 166/2025
UPC Case Law by Pitch, edited by Bart Lieben · Published
TL;DR
The Court of Appeal refused Meril's request to suspend the Munich Local Division's infringement decision in favour of Edwards Lifesciences pending Meril's appeal. Under Art 74(1) UPCA, a first-instance injunction stays enforceable during the appeal unless exceptional circumstances apply. A pending appeal against the validity decision, economic harm already weighed at first instance, and orders already complied with do not qualify.
Key holding
Under Art 74(1) UPCA an appeal has no suspensive effect (the first-instance decision is not put on hold pending the appeal) unless the appellant's interest in keeping the status quo exceptionally outweighs the respondent's interest. Examples are a manifestly erroneous decision, meaning findings that are clearly untenable even on a summary assessment, or an appeal that would otherwise become devoid of purpose. A pending appeal against a decision upholding the patent in revocation proceedings is not in itself sufficient. Harm already weighed by the Court of First Instance when granting the orders does not justify suspension unless the decision is manifestly erroneous in that respect.
Questions decided
- Does a pending appeal against the validity decision justify suspensive effect in the infringement appeal?
- What counts as a 'manifest error' for suspensive effect under Art 74(1) UPCA?
- Is suspensive effect available for orders the appellant has already complied with?
- Does a respondent's undertaking not to publish defeat the 'devoid of purpose' argument?
- Do R 223.1 and R 352.1 RoP provide a basis for staying enforcement against security?
Full summary
Read the full analyses for free — create a free account
With a free Academy account you read the full analysis of every Court of Appeal decision: the facts and procedure, the issues, the court’s reasoning and the practice points. Your name, an e-mail address and a password; no payment, and you can delete the account yourself at any time.
In the same case
- Decision · UPC CoA 464/2024
Meril Italy Srl and others v Edwards Lifesciences Corporation
The Court of Appeal upheld EP 3 646 825 as amended by Auxiliary Request II and confirmed that Meril's Myval Octacor heart valve system infringes it.
- Decision · UPC CoA 635/2024
Meril GmbH v Respondent 1 and SWAT Medical AB
The Court of Appeal set aside a Paris Central Division order that had given a European patent attorney and his company access to all pleadings and evidence in a revocation counterclaim.
- Order · UPC CoA 635/2024
Meril GmbH v SWAT Medical AB and another
A lawyer or European Patent Attorney who is personally a party before the UPC must still be represented by someone else.
- Order · UPC CoA 636/2024
Meril Life Sciences Pvt. Ltd v Respondent 1 and SWAT Medical AB
A lawyer or European Patent Attorney who is a party before the UPC cannot represent himself and must instruct a separate authorised representative.
- Order · UPC CoA 634/2024
Meril Italy S.r.l. v SWAT Medical AB and another
A lawyer or European Patent Attorney who is personally a party before the UPC cannot represent themselves.
More on suspensive effect and enforcement
- Order · UPC CoA 176/2026
Netflix Services Germany GmbH and others v DivX, LLC
The Court of Appeal refused Netflix's request for suspensive effect against the Munich Local Division's infringement decision in favour of DivX, even though the EPO Opposition Division revoked the patent after that decision.
- Order · UPC CoA 121/2026
Academy of Military Medical Sciences v Gilead Sciences, Inc.
The automatic suspensive effect of an appeal against a revocation decision under Art 74(2) UPCA covers only the ruling on the patent's validity.
- Order · UPC CoA 312/2025
Fujifilm Corporation v Kodak GmbH and others
The Court of Appeal refused to give suspensive effect to Fujifilm's application for rehearing (Art 81 UPCA) of its own final decision of 2 June 2026.